Results 81 to 90 of about 36,927 (297)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells

Frontiers in Immunology, 2023
Myeloid derived suppressors cells (MDSC) play major roles in regulating immune homeostasis and immune responses in many conditions, including cancer.
Claudia Giannotta, Federica Autino, Massimo Massaia, Massimo Massaia   +3 more
doaj   +1 more source

Iron‐Tannic Acid Hydrogel Mediated Mild Photothermal Therapy Combined With Ferroptosis Enhances Anti‐Tumor Immunity in Colorectal Cancer

Advanced Science, EarlyView.
An injectable gelatin‐based tannic acid–iron hydrogel with mild photothermal therapy could not only induce immunogenic cell death, but also elicit ferroptosis of both tumor cells and tumor‐associated macrophages, resulting in DC maturation, T‐cell infiltration and down‐regulation of ferroptosis‐sensitive M2‐type TAMs levels.
Yuan Zhu, Xi Yu, Tao Wang, Wanyi Liu, Chang Lu, Jiani Zhong, Yujie He, Wei Li, Kunxi Zhang, Peihao Yin, Zeting Yuan   +10 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

DataSheet_1_M-MDSC in vitro generation from mouse bone marrow with IL-3 reveals high expression and functional activity of arginase 1.pdf

, 2023
Myeloid-derived suppressor cells (MDSC) represent major regulators of immune responses, which can control T cells via their inducible nitric oxide synthase (iNOS)- and arginase 1 (Arg1)-mediated effector functions.
Arpa Aintablian (15648896), Marion Heuer (15648902), Manfred B. Lutz (8069960), Sandra Strozniak (15648899)   +3 more
core   +1 more source

The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy

Bladder Cancer, 2019
Myeloid derived suppressor cells (MDSC) are immune cells that dampen immune responses. In patients with cancer, MDSC are associated with adverse oncologic outcomes and therapeutic resistance.
Kathleen Puttmann, Megan Duggan, Amir Mortazavi, Dayssy Alexandra Diaz, William E. Carson III, Debasish Sundi   +5 more
doaj   +1 more source

Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery

Frontiers in Immunology, 2019
Myeloid-derived suppressor cells (MDSC) are expanded during HIV-1 infection and correlated with disease progression. MDSC expand in the early phase of primary infection depending on TRAIL level.
Chiara Agrati, Nicola Tumino, Veronica Bordoni, Carmela Pinnetti, Andrea Sabatini, Alessandra Amendola, Isabella Abbate, Patrizia Lorenzini, Annalisa Mondi, Rita Casetti, Eleonora Cimini, Germana Grassi, Andrea Antinori, Alessandra Sacchi   +13 more
doaj   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

Advanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng, Chaoying Wei, Zhitong Niu, Jinxin Chen, Guojie Long, Yingzhen Weng, Qiufeng Liu, Yue Jiang, Panpan Wang, Ronghua Zhang, Qiang Yu, Xiaojian Wu, Wenyu Wang   +12 more
wiley   +1 more source

Improving cancer immunotherapy by targeting the STATe of MDSCs [PDF]

OncoImmunology, 2016
Cancer immunotherapy is a promising therapeutic avenue; however, in practice its efficacy is hampered by an immunosuppressive tumor microenvironment that consists of suppressive cell types like myeloid-derived suppressor cells (MDSCs). Eradication or reprogramming of MDSCs could therefore enhance clinical responses to immunotherapy.
de Haas, N., Koning, C., Spilgies, L., de Vries, I.J.M., de Vries, I.J.M., Hato, S.V.   +5 more
openaire   +3 more sources

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source